Dear editor
For clarification, we undertook bottom-up costing using individual participant data from the Low Prevalence Disorders Study in our costing study. 1 We did not use the data reported in the study by Carr et al 2 as asserted by Chong et al. 3 Chong et al have thus misunderstood and thus misrepresented our methodology in both their systematic review 4 and their response to our letter.
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Dear editor
We thank Dr Neil and Professor Carr for their clarification on the data source used in their study. 1 In this regard, we would like to highlight one of the most common challenges when conducting any systematic review, for example economic burden of schizophrenia in this case -the marked diversity in reporting among the included studies, which increases the likelihood of any potential misinterpretation. In convergence with a number of published systematic reviews of economic burden studies, [2] [3] [4] [5] there has been a consistent call for a more explicit reporting in various aspects of an economic burden study, thus readability and transparency can be enhanced. However, a standardized guide/checklist for conducting and reporting economic burden is yet to be available. On the final note, we strongly urge for the development of such a guidance document to improve the quality and clarity of an economic burden study.
